Loss of antigenicity with tissue age in breast cancer

Laboratory Investigation

Volumn 96, Issue 3, 2016, Pages 264-269

  Combs, Susan E ^a   Han, Gang ^a   Mani, Nikita ^a   Beruti, Susan ^b   Nerenberg, Michael ^c   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Biotheranostics   (United States)

^c Differential Dx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; ERBB2 PROTEIN, HUMAN; KERATIN; PARAFFIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; ANTIGENICITY; ARTICLE; BREAST CARCINOMA; CHILD; COHORT ANALYSIS; EMBEDDING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE AGE; TISSUE MICROARRAY; BREAST TUMOR; CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; TISSUE PRESERVATION;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KERATINS; KI-67 ANTIGEN; PARAFFIN EMBEDDING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TISSUE ARRAY ANALYSIS; TISSUE PRESERVATION;

EID: 84959515153     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.138     Document Type: Article

References (16)

1. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452
2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable Her2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684
3. Perez EA, Jenkins RB, Dueck AC, et al. C-myc alterations and association with patient outcome in early-stage Her2-positive breast cancer from the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial. J Clin Oncol 2011; 29: 651-659
4. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to Her2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: 240-246
5. Hayes DF, Allen J, Compton C, et al. Breaking a vicious cycle. Sci Transl Med 2013; 5: 196cm196
6. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008; 26: 5630-5637
7. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998; 51: 370-374
8. DiVito KA, Charette LA, Rimm DL, et al. Long-Term preservation of antigenicity on tissue microarrays. Lab Invest 2004; 84: 1071-1078
9. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-1949
10. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 1323-1327
11. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, Her2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750
12. Wester K, Wahlund E, Sundstrom C, et al. Paraffin section storage and immunohistochemistry. effects of time, temperature, fixation, and retrieval protocol with emphasis on P53 protein and Mib1 antigen. Appl Immunohistochem Mol Morphol 2000; 8: 61-70
13. Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor markerimmunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996; 88: 1054-1059
14. Blind C, Koepenik A, Pacyna-Gengelbach M, et al. Antigenicity testing by immunohistochemistry after tissue oxidation. J Clin Pathol 2008; 61: 79-83
15. Cukier HN, Pericak-Vance MA, Gilbert JR, et al. Sample degradation leads to false-positive copy number variation calls in multiplex realtime polymerase chain reaction assays. Anal Biochem 2009; 386: 288-290
16. Bordeaux JM, Cheng H, Welsh AW, et al. Quantitative in situ measurement of estrogen receptor MRNA predicts response to tamoxifen. PLoS One 2012; 7: e36559